




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07D 243/00	A2	(11) International Publication Number: WO 99/18085 (43) International Publication Date: 15 April 1999 (15.04.99)
(21) International Application Number: PCT/US98/21051 (22) International Filing Date: 6 October 1998 (06.10.98) (30) Priority Data: 60/061,195 6 October 1997 (06.10.97) US (71) Applicant: DU PONT PHARMACEUTICALS COMPANY [US/US]; 974 Centre Road, WR-1ST18, Wilmington, DE 19807 (US). (72) Inventors: STONE, Benjamin, R., P.; 1417 Ponds Edge Road, West Chester, PA 19382 (US). ANZALONE, Luigi; 1096 Airport Road, West Chester, PA 19380 (US). FORTUNAK, Joseph, M.; 19 Somerset Lane, Newark, DE 19711 (US). HARRIS, Gregory, D.; 304 Spalding Road, Wilmington, DE 19803 (US). VALVIS, Ioannis, I.; 451 Stella Drive, Hockessin, DE 19707 (US). WALTERMIRE, Robert, E.; 1103 Hillside Boulevard, Wilmington, DE 19808 (US). (74) Agent: LARSEN, Scott, K.; Du Pont Pharmaceuticals Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).		(81) Designated States: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: PREPARATION OF ASYMMETRIC CYCLIC UREAS THROUGH A MONOACYLATED DIAMINE INTERMEDIATE  (I-a) (57) Abstract The present invention concerns an improved process for the preparation of asymmetric cyclic ureas as well as intermediates in the preparation of asymmetric cyclic ureas. In the process, a diamine of formula (I-a) is selectively monoacylated to give an asymmetric monoacylated diamine which can be converted into asymmetric intermediates. The asymmetric intermediates can be further alkylated, cyclized, and/or modified to give compounds which are useful as HIV protease inhibitors for the treatment of HIV infection. The invention allows for scalable preparation of a wide variety of asymmetrical cyclic ureas.		